TRCT
ARTV

Tower Research Capital (TRC)’s Artiva Biotherapeutics ARTV Stock Holding History

Tower Research Capital (TRC)’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,103
Closed -$4.73K – 5656
2025
Q4 		$4.73K Sell
1,103
-8,878
-89% -$33.5K ﹤0.01% 4182
2025
Q3 		$28.6K Sell
9,981
-117
-1% -$313 ﹤0.01% 2981
2025
Q2 		$15.2K Buy
10,098
+7,484
+286% +$15.7K ﹤0.01% 3820
2025
Q1 		$7.84K Buy
2,614
+1,402
+116% +$7.57K ﹤0.01% 3930
2024
Q4 		$12.2K Buy
1,212
+492
+68% +$5.91K ﹤0.01% 3639
2024
Q3 		$11.1K Buy
+720
New +$8.34K ﹤0.01% 3692

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Tower Research Capital (TRC)'s ARTV Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of Artiva Biotherapeutics (ARTV) in Q1 2026, closing a stake of 1,103 shares — an estimated $4.73K sold.

Tower Research Capital (TRC) first reported a position in ARTV in Q3 2024 and held it in 6 quarters. The position peaked at $28.6K in Q3 2025. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining Artiva Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,103 Artiva Biotherapeutics shares in Q1 2026, an estimated $4.73K.
  • Tower Research Capital (TRC) first reported a position in Artiva Biotherapeutics in Q3 2024 and held it in 6 quarters.
  • Tower Research Capital (TRC)'s Artiva Biotherapeutics position peaked at $28.6K in Q3 2025.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.